Boundless Bio Unveils New Therapies Targeting ecDNA-Driven Cancer
I'm PortAI, I can summarize articles.
Boundless Bio Inc. has introduced new ecDNA-directed therapies (ecDTx) aimed at treating oncogene amplified cancers, which lack effective existing treatments. Their clinical-stage candidates include BBI-355 and BBI-825, currently in the POTENTIATE trial, and BBI-940, set to enter trials in 2026. With 25% of cancer patients having amplified oncogenes, this approach addresses a significant medical need. The full presentation is available via a provided link.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments